DOCS vs. RMG, VTY, TEM, SPT, GEN, WIX, YOU, CNIC, SRAD, and SLP
Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Royal Mail (RMG), Vistry Group (VTY), Templeton Emerging Markets Investment Trust (TEM), Spirent Communications (SPT), Genuit Group (GEN), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Stelrad Group (SRAD), and Sylvania Platinum (SLP). These companies are all part of the "computer software" industry.
Dr. Martens vs.
Dr. Martens (LON:DOCS) and Royal Mail (LON:RMG) are both small-cap consumer cyclical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 5.1%. Royal Mail pays an annual dividend of GBX 0.17 per share. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Royal Mail pays out 27.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
In the previous week, Dr. Martens had 3 more articles in the media than Royal Mail. MarketBeat recorded 3 mentions for Dr. Martens and 0 mentions for Royal Mail. Dr. Martens' average media sentiment score of 0.21 beat Royal Mail's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the media.
Dr. Martens currently has a consensus price target of GBX 6,000, suggesting a potential upside of 10,052.28%. Given Dr. Martens' stronger consensus rating and higher possible upside, research analysts plainly believe Dr. Martens is more favorable than Royal Mail.
Royal Mail received 513 more outperform votes than Dr. Martens when rated by MarketBeat users. However, 84.62% of users gave Dr. Martens an outperform vote while only 54.30% of users gave Royal Mail an outperform vote.
Dr. Martens has higher earnings, but lower revenue than Royal Mail. Royal Mail is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.
Dr. Martens has a net margin of 7.89% compared to Royal Mail's net margin of 0.00%. Dr. Martens' return on equity of 18.91% beat Royal Mail's return on equity.
69.5% of Dr. Martens shares are owned by institutional investors. 4.4% of Dr. Martens shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Dr. Martens beats Royal Mail on 12 of the 16 factors compared between the two stocks.
Get Dr. Martens News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Martens Competitors List
Related Companies and Tools
This page (LON:DOCS) was last updated on 6/4/2025 by MarketBeat.com Staff
